Indivior PLC (NASDAQ:INDV – Get Free Report) saw a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 2,060,000 shares, a growth of 68.9% from the February 13th total of 1,220,000 shares. Based on an average trading volume of 1,440,000 shares, the days-to-cover ratio is currently 1.4 days. Currently, 1.9% of the shares of the stock are short sold.
Analysts Set New Price Targets
Several research firms have issued reports on INDV. Rodman & Renshaw began coverage on Indivior in a report on Tuesday, January 28th. They set a “buy” rating and a $16.00 price objective on the stock. RODMAN&RENSHAW upgraded Indivior to a “strong-buy” rating in a report on Tuesday, January 28th. Finally, Piper Sandler cut their price objective on Indivior from $16.00 to $13.00 and set an “overweight” rating on the stock in a report on Thursday, March 6th.
Read Our Latest Report on Indivior
Hedge Funds Weigh In On Indivior
Indivior Trading Up 0.9 %
NASDAQ INDV opened at $9.68 on Monday. The company has a market cap of $1.33 billion, a PE ratio of -27.66 and a beta of 0.82. Indivior has a 1 year low of $7.33 and a 1 year high of $22.53. The stock’s 50-day moving average price is $10.64 and its two-hundred day moving average price is $10.48.
Indivior (NASDAQ:INDV – Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported $0.32 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.32. The company had revenue of $298.00 million for the quarter, compared to the consensus estimate of $262.35 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. Research analysts forecast that Indivior will post 1.22 EPS for the current fiscal year.
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
- Five stocks we like better than Indivior
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- How to Build the Ultimate Everything ETF Portfolio
- How to Invest in Blue Chip Stocks
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What is the Shanghai Stock Exchange Composite Index?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.